WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL

Míreanna comhchosúla

• WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
  de réir: Jonathan Barratt, et al.
  Foilsithe / Cruthaithe: (2024-04-01)
• WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
  de réir: Jonathan Barratt, et al.
  Foilsithe / Cruthaithe: (2024-04-01)
• WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL
  de réir: Jonathan Barratt, et al.
  Foilsithe / Cruthaithe: (2024-04-01)
• WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
  de réir: Bruce Hendry, et al.
  Foilsithe / Cruthaithe: (2025-02-01)
• WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
  de réir: Vivekanand Jha, et al.
  Foilsithe / Cruthaithe: (2025-02-01)